Skip to main content

Table 2 Univariable and multivariable Cox regression analysis of the four-lncRNA signature and overall survival in each dataset

From: Identification and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma

Variables Univariate analysisa Multivariable analysisa
HR 95 % CI of HR P Value HR 95 % CI of HR P Value
Training dataset (n = 280)
lncRNA-focus risk score 2.718 1.937–3.815 7.262E-09 2.066 1.395–3.060 2.94E-04
Age 1.032 1.008–1.056 0.008 1.020 0.997–1.044 0.090
Gender (female/male) 0.844 0.556–1.280 0.424 1.047 0.665–1.648 0.842
Total Therapy (TT2/TT3) 0.914 0.572–1.462 0.709 1.060 0.648–1.735 0.816
IgA isotype (N/Y) 1.044 0.654–1.666 0.857 1.032 0.794–2.134 0.295
Serum beta 2-microglobulin ≥ 3.5 mg/L (N/Y) 2.677 1.742–4.112 6.99E-06 1.733 1.057–2.843 0.029
C-reactive protein ≥ 8.0 mg/L (N/Y) 1.749 1.155–2.648 0.008 1.008 0.628–1.616 0.975
Creatinine ≥ 2.0 mg/dL (177 μmol/L) (N/Y) 3.821 2.338–6.245 8.84E-08 1.864 0.992–3.501 0.053
Lactate dehydrogenase > upper limit of normal (>190 U/L) (N/Y) 2.651 1.749–4.017 4.33E-06 1.484 0.928–2.371 0.099
Serum albumin <35 g/ L (N/Y) 2.003 1.228–3.266 0.005 1.559 0.929–2.618 0.093
Testing dataset (n = 279)
lncRNA-focus risk score 1.579 1.099–2.270 0.014 1.726 1.113–2.675 0.015
Age 1.015 0.991–1.039 0.223 1.006 0.982–1.031 0.616
Gender (female/male) 1.130 0.722–1.768 0.593 1.667 0.981–2.831 0.059
Total Therapy (TT2/TT3) 0.651 0.368–1.150 0.139 0.590 0.329–1.060 0.077
IgA isotype (N/Y) 1.189 0.724–1.953 0.494 1.428 0.837–2.438 0.192
Serum beta 2-microglobulin ≥ 3.5 mg/L (N/Y) 1.866 1.206–2.888 0.005 1.470 0.886–2.437 0.136
C-reactive protein ≥ 8.0 mg/L (N/Y) 1.233 0.786–1.932 0.362 1.158 0.734–1.828 0.529
Creatinine ≥ 2.0 mg/dL (177 μmol/L) (N/Y) 1.774 0.937–3.359 0.078 0.954 0.467–1.946 0.896
Lactate dehydrogenase > upper limit of normal (>190 U/L) (N/Y) 1.993 1.283–3.097 0.002 1.918 1.133–3.249 0.015
Serum albumin <35 g/ L (N/Y) 1.877 1.055–3.340 0.032 1.791 0.933–3.437 0.080
Entire GSE24080 dataset (n = 559)
lncRNA-focus risk score 2.099 1.638–2.688 4.404E-09 1.905 1.434–2.530 8.65E-06
Age 1.024 1.007–1.041 0.005 1.013 0.996–1.030 0.128
Gender (female/male) 0.973 0.717–1.319 0.860 1.338 0.955–1.875 0.090
Total Therapy (TT2/TT3) 0.797 0.556–1.143 0.218 0.805 0.554–1.168 0.254
IgA isotype (N/Y) 1.106 0.787–1.555 0.561 1.261 0.888–1.791 0.194
Serum beta 2-microglobulin ≥ 3.5 mg/L (N/Y) 2.236 1.651–3.028 2.0E-07 1.574 1.111–2.231 0.011
C-reactive protein ≥ 8.0 mg/L (N/Y) 1.485 1.097–2.011 0.011 1.123 0.818–1.543 0.474
Creatinine ≥ 2.0 mg/dL (177 μmol/L) (N/Y) 2.730 1.856–4.015 3.35E-07 1.377 0.877–2.160 0.165
Lactate dehydrogenase > upper limit of normal (>190 U/L) (N/Y) 2.317 1.714–3.133 4.77E-08 1.645 1.180–2.294 0.003
Serum albumin <35 g/ L (N/Y) 1.946 1.342–2.821 4.47E-04 1.519 1.028–2.245 0.036
GSE57317 dataset (n = 55)b
lncRNA-focus risk score 2.640 1.013–6.879 0.047    
GSE9782 dataset (n = 264)
lncRNA-focus risk score 1.637 1.107–2.42 0.014 1.909 1.269–2.870 0.002
Age 1.014 0.998–1.03 0.087 1.016 0.999–1.032 0.054
Gender (female/male) 1.334 0.961–1.853 0.086 1.543 1.098–2.169 0.012
  1. alncRNA-focus risk score and age were evaluated as continuous variables in both univariate and multivariate Cox regression analysis
  2. bThere was no available clinical features in GSE57317 dataset